GSE143317 dataset shows elevated FCRL5 expression in PCs of relapsed MM patients after CAR-T cell therapy targeting BCMA (Fig. 1c), and elevated FCRL5 expression was associated with shorter disease-free survival times (Fig. 1d, Supplementary Fig. S1c). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.